Benitec Biopharma grants COO Sophie Mukadam 300,000 options at $12.00

Benitec Biopharma Inc.

Sophie Mukadam appointed COO effective Jan 1, 2025; receives 300,000 nonqualified stock options.
Exercise price $12.00 per share, equal to closing price on grant date Dec 27, 2024.
Vesting in 16 equal quarterly installments starting Mar 31, 2025, conditioned on continued service.
Unvested options fully accelerate upon a Change in Control as defined in the Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.